Published in Int J Oncol on June 10, 2014
Epigenetics and miRNA as predictive markers and targets for lung cancer chemotherapy. Cancer Biol Ther (2015) 0.79
Genomic and functional analysis of the host response to acute simian varicella infection in the lung. Sci Rep (2016) 0.75
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med (2011) 38.61
Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet (1999) 13.67
Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med (2005) 13.01
The new lung cancer staging system. Chest (2009) 6.30
Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med (2011) 3.74
Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol (2005) 3.48
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 3.06
Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol (2007) 2.93
Evidence for the treatment of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 2.72
Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer (2007) 2.20
Emerging roles for phospholipase A2 enzymes in cancer. Biochimie (2010) 1.86
Increasing molecular diversity of secreted phospholipases A(2) and their receptors and binding proteins. Biochim Biophys Acta (2000) 1.76
Receptors for a growing family of secreted phospholipases A2. Trends Pharmacol Sci (1999) 1.69
Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr Opin Pharmacol (2006) 1.57
Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. Clin Cancer Res (2006) 1.50
Knockdown of secretory phospholipase A2 IIa reduces lung cancer growth in vitro and in vivo. J Thorac Cardiovasc Surg (2012) 1.49
Lung cancer surgery. A critical review of the evidence. Arch Intern Med (1994) 1.44
Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Clin Cancer Res (2004) 1.37
First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. J Thorac Oncol (2010) 1.33
Role of the MRP1/ABCC1 multidrug transporter protein in cancer. IUBMB Life (2007) 1.27
Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy. Cancer Metastasis Rev (2010) 1.26
Secretory phospholipases A2 in inflammatory and allergic diseases: not just enzymes. J Allergy Clin Immunol (2005) 1.25
Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Lung Cancer (2009) 1.24
Phospholipase A2 as targets for anti-cancer drugs. Biochem Pharmacol (2007) 1.23
Oncogenic action of secreted phospholipase A2 in prostate cancer. Cancer Res (2004) 1.21
The role of the ErbB family members in non-small cell lung cancers sensitive to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res (2006) 1.20
Lung cancer in 2010: One size does not fit all. Nat Rev Clin Oncol (2011) 1.20
Incorporating bortezomib into the treatment of lung cancer. Clin Cancer Res (2007) 1.17
Decreased lung tumorigenesis in mice genetically deficient in cytosolic phospholipase A2. Carcinogenesis (2004) 1.16
Production of vascular endothelial growth factors from human lung macrophages induced by group IIA and group X secreted phospholipases A2. J Immunol (2010) 1.09
Molecular mechanisms of androgen-independent growth of human prostate cancer LNCaP-AI cells. Endocrinology (1999) 1.03
Cytosolic phospholipase A2-alpha: a potential therapeutic target for prostate cancer. Clin Cancer Res (2008) 1.01
Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer. Carcinogenesis (2010) 0.95
Can lung cancer screening by computed tomography be effective in areas with endemic histoplasmosis? J Thorac Cardiovasc Surg (2010) 0.95
Secretory phospholipase A2 activates the cascade of mitogen-activated protein kinases and cytosolic phospholipase A2 in the human astrocytoma cell line 1321N1. J Biol Chem (1998) 0.95
Expression of secretory phospholipase A2 in colon tumor cells potentiates tumor growth. Mol Carcinog (2007) 0.91
Secreted PLA2 induces proliferation in astrocytoma through the EGF receptor: another inflammation-cancer link. Neuro Oncol (2010) 0.91
Secretory phospholipase A2-IIa is a target gene of the HER/HER2-elicited pathway and a potential plasma biomarker for poor prognosis of prostate cancer. Prostate (2011) 0.89
The role of proteasome inhibition in nonsmall cell lung cancer. J Biomed Biotechnol (2011) 0.87
Gene therapy targeting nuclear factor-kappaB: towards clinical application in inflammatory diseases and cancer. Curr Gene Ther (2009) 0.86
Plasma secretory phospholipase A2-IIa as a potential biomarker for lung cancer in patients with solitary pulmonary nodules. BMC Cancer (2011) 0.86
Expression of enhancing factor/phospholipase A2 in skin results in abnormal epidermis and increased sensitivity to chemical carcinogenesis. Oncogene (2003) 0.82
Secreted phospholipase A2-IIA modulates key regulators of proliferation on astrocytoma cells. J Neurochem (2009) 0.81
Vav3 oncogene is involved in regulation of secretory phospholipase A2-IIa expression in prostate cancer. Oncol Rep (2011) 0.81
Akt as a mediator of secretory phospholipase A2 receptor-involved inducible nitric oxide synthase expression. J Immunol (2003) 0.81
Group IIA secretory phospholipase A(2) stimulates inducible nitric oxide synthase expression via ERK and NF-kappaB in macrophages. Eur J Immunol (2001) 0.80
Inflammatory protein sPLA(2)-IIA abrogates TNFalpha-induced apoptosis in human astroglioma cells: Crucial role of ERK. Biochim Biophys Acta (2009) 0.78